Asian responders rescue motesanib in NSCLC but Amgen offloads rights to Takeda
This article was originally published in Scrip
Executive Summary
The failure of Amgen/Takeda's motesanib in the Phase III MONET1 study in advanced non-squamous non-small cell lung cancer (NSCLC) last year could have dealt the final blow to the molecule in this indication, for which most analysts were already assuming zero sales.